Ignite Creation Date:
2024-05-06 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05279378
Status:
RECRUITING
Last Update Posted:
2022-04-22
First Post:
2022-03-11
Brief Title:
Correlation of Lung Ultrasonography With Chest CT Findings in Cancer Patients With COVID-19 Viral Pneumonia
Sponsor:
South Egypt Cancer Institute
Organization:
South Egypt Cancer Institute
Study Overview
Official Title:
Correlation of Lung Ultrasonography With Chest CT Findings in Cancer Patients With COVID-19 Viral Pneumonia an Observational Study
Status:
RECRUITING
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Thoracic imaging either with chest X-ray CXR or computed tomography CT is an essential part of the diagnosis of coronavirus disease-19 COVID-19 in patients admitted to hospital with fever or respiratory symptoms
Inspite of the results of PCR tests are the gold standard the sensitivity of CT for diagnosing COVID-19 is 97 The specific epidemic contingency makes CT an accurate tool to stratify patients based on imaging patterns predicting poor outcomes and the need for ventilation
Lung ultrasound LUS is widely used in emergency departments because it is broadly available low-cost and has a high accuracy for diagnosing pulmonary diseases
Despite the diagnostic power of LUS and its influence on decision-making and therapeutic management there are still significant barriers to the widespread use of this tool
The advantages of LUS are more obvious in older patients with multimorbidity and restricted mobility for whom high-quality CXR and CT scans are difficult to obtain In the hands of experienced clinicians LUS diagnostic accuracy for bacterial pneumonia is similar to chest CT
However a correlation between LUS and CT findings in patient urgently hospitalized for severe COVID-19 pneumonia remains to be determined
COVID-19 leads to an aggressive inflammatory response that is actually the reaction of the immune system Some patients exhibit pneumonia in both lungs multi-organ failure and even death Individuals who have severe health conditions like cancer cardiovascular diseases diabetes and pulmonary diseases are at higher risk of COVID-19 infection
Also this dysregulated immune response resulting in excessive production of inflammatory cytokines and chemokines as IL-1ra IL-6 IP-10 G-CSF MCP-1 MIP-1α and TNF causes the development of cytokine release syndrome CRS which is considered as pathologic underpinning for disease progression and lead to severe collateral tissue damage
IL-6 may serve as a predictive biomarker for disease severity as its elevated levels were reported in several studies of COVID-19 infection Also IL-6 levels were correlated with mortality in COVID-19 patients IL-6 blockade is a promising strategy for COVID-induced CRS
In particular clinical epidemiological studies are needed to determine if IL-6 andor other inflammatory cytokine levels predict subsequent development and persistence of long COVID 19 viral pneumonia
Inspite of the results of PCR tests are the gold standard the sensitivity of CT for diagnosing COVID-19 is 97 The specific epidemic contingency makes CT an accurate tool to stratify patients based on imaging patterns predicting poor outcomes and the need for ventilation
Lung ultrasound LUS is widely used in emergency departments because it is broadly available low-cost and has a high accuracy for diagnosing pulmonary diseases
Despite the diagnostic power of LUS and its influence on decision-making and therapeutic management there are still significant barriers to the widespread use of this tool
The advantages of LUS are more obvious in older patients with multimorbidity and restricted mobility for whom high-quality CXR and CT scans are difficult to obtain In the hands of experienced clinicians LUS diagnostic accuracy for bacterial pneumonia is similar to chest CT
However a correlation between LUS and CT findings in patient urgently hospitalized for severe COVID-19 pneumonia remains to be determined
COVID-19 leads to an aggressive inflammatory response that is actually the reaction of the immune system Some patients exhibit pneumonia in both lungs multi-organ failure and even death Individuals who have severe health conditions like cancer cardiovascular diseases diabetes and pulmonary diseases are at higher risk of COVID-19 infection
Also this dysregulated immune response resulting in excessive production of inflammatory cytokines and chemokines as IL-1ra IL-6 IP-10 G-CSF MCP-1 MIP-1α and TNF causes the development of cytokine release syndrome CRS which is considered as pathologic underpinning for disease progression and lead to severe collateral tissue damage
IL-6 may serve as a predictive biomarker for disease severity as its elevated levels were reported in several studies of COVID-19 infection Also IL-6 levels were correlated with mortality in COVID-19 patients IL-6 blockade is a promising strategy for COVID-induced CRS
In particular clinical epidemiological studies are needed to determine if IL-6 andor other inflammatory cytokine levels predict subsequent development and persistence of long COVID 19 viral pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None